Roy S. Herbst, MD, PhD
机构: Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven
每年引用次数
引用次数
引用: 105,712
H-指数: 146
I10-指数 : 487
出版物: 998
Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents
Rogerio C. Lilenbaum , Roy S. Herbst
Clinical Pulmonary Medicine 15 ( 6) 352 -358
2008
Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324
George R. Blumenschein , Rebecca Paulus , Walter J. Curran , Francisco Robert
Journal of Clinical Oncology 29 ( 17) 2312 -2318
145
2011
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Hai T. Tran , Ralph G. Zinner , George R. Blumenschein , Yun W. Oh
Investigational New Drugs 29 ( 3) 499 -505
19
2011
Targeting Vascular Endothelial Growth Factor in Patients With Squamous Cell Lung Cancer
Peter J. Koo , Daniel Morgensztern , Julie L. Boyer , Roy S. Herbst
Journal of Clinical Oncology 30 ( 10) 1137 -1139
7
2012
Tobacco Assessment in Actively Accruing National Cancer Institute Cooperative Group Program Clinical Trials
Erica N. Peters , Essie Torres , Benjamin A. Toll , K. Michael Cummings
Journal of Clinical Oncology 30 ( 23) 2869 -2875
43
2012
A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.
Roy S. Herbst , Alfonso Gurpide , Veerle Surmont , Dong-Wan Kim
Journal of Clinical Oncology 32
4
2014
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Jean-Charles Soria , José Baselga , Nasser Hanna , Scott A. Laurie
European Journal of Cancer 49 ( 8) 1815 -1824
15
2013
Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial
Charles Lu , J. Jack Lee , Ritsuko Komaki , Roy S. Herbst
Journal of the National Cancer Institute 102 ( 12) 859 -865
55
2010
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle , Lauren A. Byers , Edward S. Kim , Pierre Saintigny
Journal of the National Cancer Institute 104 ( 3) 228 -239
294
2012
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
Carolyn J. Presley , Daiwei Tang , Pamela R. Soulos , Anne C. Chiang
JAMA 320 ( 5) 469 -477
55
2018
Immune Checkpoint Inhibitor–Associated Pericarditis
Mehmet Altan , Maria I. Toki , Scott N. Gettinger , Daniel E. Carvajal-Hausdorf
Journal of Thoracic Oncology 14 ( 6) 1102 -1108
27
2019
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
Jong Woo Lee , Yu Zhang , Kyung Jin Eoh , Roshan Sharma
Journal of Thoracic Oncology 14 ( 6) 1046 -1060
22
2019
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC
Fabrice Barlesi , Edward B. Garon , Dong-Wan Kim , Enriqueta Felip
Journal of Thoracic Oncology 14 ( 5) 793 -801
17
2019
SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Martin J. Edelman , Mary W. Redman , Kathy S. Albain , Eric C. McGary
Journal of Thoracic Oncology 14 ( 10) 1853 -1859
13
2019
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Corey J. Langer , Mary W. Redman , James L. Wade , Charu Aggarwal
Journal of Thoracic Oncology 14 ( 10) 1839 -1846
17
2019
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Charu Aggarwal , Mary W. Redman , Primo N. Lara , Hossein Borghaei
Journal of Thoracic Oncology 14 ( 10) 1847 -1852
26
2019
Role of Chitinase 3–like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis
Bing Ma , Erica L. Herzog , Chun Geun Lee , Xueyan Peng
Cancer Research 75 ( 3) 487 -496
52
2015
CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma
Pierre Saintigny , Erminia Massarelli , Steven Lin , Young-Ho Ahn
Cancer Research 73 ( 2) 571 -582
95
2013
Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis.
Asawari Korde , Lei Jin , Jian-ge Zhang , Anuradha Ramaswamy
American Journal of Respiratory and Critical Care Medicine 196 ( 11) 1443 -1455
15
2017
Enhancing insights into pulmonary vascular disease through a precision medicine approach: A joint nhlbi-cardiovascular medical research and education fund workshop report
John H. Newman , Stuart Rich , Steven H. Abman , John H. Alexander
American Journal of Respiratory and Critical Care Medicine 195 ( 12) 1661 -1670
41
2017